We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Novartis has inked a deal with San Diego-based biotechnology company Anadys Pharmaceuticals to develop, manufacture and commercialize ANA975, a new treatment for the hepatitis C virus (HCV).
Novartis has agreed to sell products in three European countries to gain final European Union (EU) approval for its planned merger of German generic drugmaker Hexal AG and Hexal's U.S. sister company Eon Labs, the European Commission (EC) announced May 27.
Merck has signed a multimillion-dollar drug development deal that will give it exclusive rights to a sepsis product candidate owned by Italian biotechnology firm BioXell.
International generic drug company Actavis Group is expanding into the U.S. market through the purchase of privately held U.S. generic firm Amide Pharmaceutical.
Andrx has signed a deal with Amphastar Pharmaceuticals to purchase partial U.S. marketing rights to a generic version of sanofi-aventis’ blockbuster thrombosis treatment Lovenox.
KV Pharmaceuticals will acquire worldwide marketing rights to an endometriosis treatment and North American marketing rights to 10 generic drugs as a result of two recent deals.
Novartis is considering divesting a small group of pharmaceutical products as a means to gain European Union (EU) approval for its acquisition of German generics company Hexal AG.
KV Pharmaceuticals will acquire worldwide marketing rights to an endometriosis treatment as well as U.S. and Canadian marketing rights for 10 generic drugs as a result of two recent deals.